<?xml version="1.0" encoding="UTF-8"?>
<results title="tropicalVirus">
 <result pre="fever virus, and Rift Valley fever virus, as well as" exact="Chikungunya" post="virus, which is on the WHO watch list. The"/>
 <result pre="fÃ¼r zukÃ¼nftige klinische Studien in entsprechenden Risikogebieten. Keywords Nipah MERS-CoV" exact="Chikungunya" post="Rift Valley fever CEPI SchlÃ¼sselwÃ¶rter Nipah MERS-CoV Chikungunya Rifttalfieber"/>
 <result pre="Nipah MERS-CoV Chikungunya Rift Valley fever CEPI SchlÃ¼sselwÃ¶rter Nipah MERS-CoV" exact="Chikungunya" post="Rifttalfieber Coalition for Epidemic Preparedness Innovation Background Global trends,"/>
 <result pre="2012, Ebola virus in 2013â€&quot;2016 and from 2018 onward, and" exact="Zika" post="virus in 2015â€&quot;16 are some examples [5â€&quot;9]. In each"/>
 <result pre="high-priority pathogens, which currently include Lassa, MERS-CoV, Nipah, RVF, and" exact="Chikungunya" post="viruses. The second is the development of vaccine platform"/>
 <result pre="pathogens, supporting candidate vaccines against MERS-CoV, Nipah, Lassa, RVF, and" exact="Chikungunya" post="viruses. The second CfP aims to advance rapid-response platforms"/>
 <result pre="Bioscience Lassa US$58.5 million Recombinant virus PhaseÂ I MERS-CoV Preclinical" exact="Chikungunya" post="PhaseÂ III University of Tokyo Nipah US$31.0 million Recombinant"/>
 <result pre="Rift Valley fever US$12.5 million Attenuated virus PhaseÂ I Valneva" exact="Chikungunya" post="US$23.4 million Attenuated virus PhaseÂ I Public health vaccines"/>
 <result pre="Rabies CureVac Lassa US$34.0 million RNA Preclinical PhaseÂ I Rabies" exact="Yellow fever" post="University of Queensland MERS-CoV US$10.6 million Recombinant protein Preclinical"/>
</results>
